Sakar Healthcare share news, announcements and annual reports
NSE: SAKARPharmaceuticals & BiotechnologySmall Cap
Sakar Healthcare Limited · Face value ₹10 Face value. The nominal value of one share as the company issued it, the unit its share capital is counted in and a dividend can be stated as a percentage of; it has no link to the share price. Face value in the glossary · Listed Oct 2016 · Issue price ₹56
Last close ₹944.80down ₹1.70 (0.18%)
Share price at the NSE close on 30 Oct 2026. Previous close ₹946.50.
30 Oct: open ₹947.00, high ₹980.00, low ₹936.10
52-week range of traded prices to 30 Oct 2026
₹352.20Low, 30 Oct 2025₹1,229.85High, 23 Sep 2026
- Under NSE's long-term additional surveillance, stage I, on the list for 30 Oct 2026. The exchange puts a share here when its price has moved unusually, and trading in it carries extra conditions.
- Market capMarket capitalisation. Share price times the number of shares: what the whole company is worth at the day's price. The rank is by average market value over the six months to Jun 2026, among listed companies. Market capitalisation: how it is worked out
- ₹2,102 Cr1,357th largest listed
- P/EPrice to earnings, trailing. Market cap divided by the profit of the last twelve months (the latest four quarters, or two half years for a company that reports half-yearly) that belongs to the company's own shareholders, after the share of the other owners of its subsidiaries: what investors pay for each rupee of a year's profit. Price to earnings, trailing: how it is worked out
- 49.04
- P/BPrice to book. Market cap divided by the net worth that belongs to the company's own shareholders, its assets less everything it owes and less the other owners' share of its subsidiaries, on its latest balance sheet. Price to book: how it is worked out
- 6.08
- Dividend yieldDividend yield. Dividends paid per share in the twelve months to the day, as a percentage of the day's share price.
- Nonein the last 12 months
- ROEReturn on equity. Profit over the last twelve months (the latest four quarters, or two half years for a company that reports half-yearly) that belongs to the company's own shareholders, as a percentage of their net worth, the money they have in the business. Net worth is the average of the latest balance sheet and the one a year before it.
- 13.2%
- ROCEReturn on capital employed. Operating profit after depreciation (revenue less operating expenses and depreciation, without other income and one-off items) as a percentage of all the money the business runs on: the whole group's net worth, the other owners of its subsidiaries included, plus borrowings. Lease liabilities are not counted: the results filings do not state them. The profit is over the last twelve months (the latest four quarters, or two half years for a company that reports half-yearly); net worth and borrowings are on the latest balance sheet.
- 16.6%
- Debt to equityDebt to equity. Borrowings divided by the whole group's net worth, the other owners of its subsidiaries included: rupees borrowed for each rupee of equity in the business. Lease liabilities are not counted: the results filings do not state them. From the balance sheet at the end of Sep 2026.
- 0.13
- Volume, NSEVolume. Shares traded on the last trading day; delivery is the part buyers kept rather than sold again the same day. Volume in the glossary
- 1,26,62743.6% delivered
Sakar Healthcare disputes and clarifications
19 filed, newest first.
Jun 2026
May 2026
22 May · Legal
Exchange has sought clarification from Sakar Healthcare Limited for the quarter ended 31-Mar-2026 with respect to Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. On basis of above the Company is required to clarify the following: -1. Financial results submitted is not as per format prescribed by SEBI. -2. Limited Review Report/ Independent Auditor's Report is not in the format prescribed by SEBI. The response of the Company is awaited.
Feb 2026
17 Feb · Legal
Exchange has sought clarification from Sakar Healthcare Limited for the quarter ended 31-Dec-2025 with respect to Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. On basis of above the Company is required to clarify the following: -1. Financial results submitted is not as per format prescribed under Schedule III of the Companies Act. -2. 2013 or as per Indian Accounting Standard. The response of the Company is awaited.
Jan 2026
12 Jan · Legal
Exchange has sought clarification from Sakar Healthcare Limited for the quarter ended 30-Sep-2025 with respect to Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. On basis of above the Company is required to clarify the following: -1. Financial results submitted is not as per format prescribed under Schedule III of the Companies Act, 2013 or as per Indian Accounting Standard The response of the Company is awaited.
Mar 2023
1 Mar · Legal
Exchange has sought clarification from Sakar Healthcare Limited for the quarter ended 31-Dec-2022 with respect to Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. On basis of above the Company is required to clarify the following: -1. Limited Review Report/ Independent Auditor's Report is not in the format prescribed by SEBI The response of the Company is awaited.
Mar 2022
25 Mar · Legal
The exchange asked on 24 Mar 2022
Jul 2021
5 Jul · Legal
The exchange asked on 2 Jul 2021
May 2021
11 May · Legal
The exchange asked on 10 May 2021
Oct 2020
Sep 2020
30 Sep · Legal
Exchange has sought clarification from Sakar Healthcare Limited with respect to announcement dated 28-Sep-2020, regarding resignation of Mr Hardik P. Mehta as Independent Director of the company w.e.f. September 28, 2020. On basis of above the Company is required to clarify following: 1. No other material reasons other than providedThe response of the Company is awaited.
Dec 2019
2 Dec · Legal
Exchange has sought clarification from Sakar Healthcare Limited for the quarter ended 30-Sep-2019 with respect to Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. On basis of above the Company is required to clarify the following: -1. Financial results submitted is not as per format prescribed by SEBI The response of the Company is awaited.
Feb 2018
21 Feb · Legal
Exchange has sought clarification from Sakar Healthcare Limited with respect to announcement dated 21-Feb-2018, regarding " Sakar Healthcare Limited has informed the Exchange regarding Change in Company Secretary / Compliance Officer.". On basis of above the Company is required to clarify following: 1. Brief profile (in case of appointment); The response of the Company is awaited.
Nov 2017
20 Nov · Legal
Exchange has sought clarification from Sakar Healthcare Limited with respect to Non-compliance as per Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. On basis of above the Company is required to clarify the following: -1. Standalone limited review report not submitted The response of the Company is awaited.